type 2 diabetes – Medxy AI

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.

Clinical Updates Wellness & Lifestyle

Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials

By MedXY 08/02/2025

Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.

Clinical Updates Medical News Wellness & Lifestyle

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

Clinical Updates Wellness & Lifestyle

GLP-1 Receptor Agonists and Risk of GERD in Type 2 Diabetes: Clinical Implications from a Large Population-Based Cohort Study

By MedXY 07/31/2025

GLP-1 receptor agonists modestly increase the risk of GERD and its complications compared to SGLT-2 inhibitors in type 2 diabetes patients, highlighting the need for vigilant symptom monitoring.

Clinical Updates Wellness & Lifestyle

GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation

By MedXY 07/31/2025

A large-scale emulated trial found no clear overall reduction in dementia risk with GLP-1 receptor agonists versus DPP-4 inhibitors in older adults with type 2 diabetes, though age-specific effects warrant further investigation.